Gossamer Bio filings document a clinical-stage biopharmaceutical issuer centered on seralutinib for PAH and PH-ILD. Form 8-K reports cover operating and financial results, Phase 3 PROSERA clinical disclosures, material agreements, unregistered equity issuances, resource-allocation actions, and Nasdaq listing-compliance notices involving its common stock.
Proxy materials describe board governance, shareholder voting matters, executive compensation, equity awards, and incentive-plan administration. The filing record also documents capital-structure matters and formal disclosures connected to a late-stage pulmonary hypertension development company.
Gossamer Bio, Inc. (GOSS) reported a Form 4 for Chief Development Officer Caryn Peterson showing a grant of stock options for 5,800,051 shares of common stock on 2026-08-24, at an exercise price of $0.175 per share, expiring on 2036-08-23.
According to the vesting terms, 50% of the option vests upon FDA approval of seralutinib. The remaining 50% then vests in 24 equal monthly installments after that approval, subject to continued service. If FDA approval has not occurred within two years of the grant date, the entire option instead vests in 24 equal monthly installments starting two years after the grant date, also subject to continued service.
Gossamer Bio, Inc. (GOSS) reported that Chief Commercial Officer Robert Paul Smith Jr. received a stock option grant for 5,800,051 shares of common stock on August 24, 2026. The option has an exercise price of $0.175 per share and expires on August 23, 2036. According to the vesting terms, 50% of the shares vest upon FDA approval of seralutinib, and the remaining 50% vest in 24 equal monthly installments after that approval, subject to continuous service. If FDA approval has not occurred within two years of the grant date, vesting instead begins in 24 equal monthly installments starting two years after the grant date, also subject to continued service.
Gossamer Bio, Inc. (GOSS) reported that its COO/CFO, Bryan Giraudo, acquired derivative securities. A family trust received 25 Pre-Funded Warrants, each initially exercisable for Series A-1 non-voting convertible preferred stock at an exercise price of $0.0001 per share, with no expiration date. Each Series A-1 share is automatically convertible, upon stockholder approval under applicable Nasdaq rules for the related private placement, into common stock equal to $1,000 divided by $0.14, subject to beneficial ownership limitations.
Separately, Giraudo was granted a stock option over 5,800,051 shares of common stock at an exercise price of $0.175 per share, expiring on August 23, 2036. According to the vesting terms, 50% of the option vests upon FDA approval of seralutinib, and the remaining 50% vests in 24 equal monthly installments after that approval; if such approval has not occurred within two years of grant, vesting shifts to 1/24th monthly beginning two years after grant, in each case subject to his continuous service.
Gossamer Bio, Inc. (GOSS) reported that President & CEO Faheem Hasnain acquired two derivative awards. A family trust received 166 Pre-Funded Warrants exercisable at $0.0001 per share into Series A-1 preferred stock, which is automatically convertible after stockholder approval into common stock per a $1,000 ÷ $0.14 formula. Separately, Hasnain was granted 5,800,051 stock options for common stock at an exercise price of $0.175 per share, expiring in 2036, with vesting tied primarily to FDA approval of seralutinib or, failing that by two years after grant, a monthly time-based vesting schedule.
Gossamer Bio, Inc. (GOSS) reported that on August 24, 2026 it amended its amended and restated certificate of incorporation in connection with the closing of a previously announced private placement. The company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A-1 Convertible Preferred Stock with the Delaware Secretary of State, formally creating this preferred stock series.
The rights and preferences of the Series A-1 Convertible Preferred Stock are described in a prior report under Item 1.01 filed on August 21, 2026 and are further detailed in the Certificate of Designation attached as Exhibit 3.1 to this report.
Gossamer Bio, Inc. (GOSS) is the subject of an Amendment No. 3 to a Schedule 13D filed by investment entities associated with D. E. Shaw. The amendment updates the description of these entities and restates their beneficial ownership and control relationships in Gossamer Bio’s common stock.
Based on 488,846,722 common shares outstanding as of August 8, 2026, D. E. Shaw Valence Portfolios, L.L.C. holds 27,698,267 shares, or 5.7%, and D. E. Shaw Cogence Portfolios, L.L.C. holds 1,429,927 shares, or 0.3%. Through advisory and management roles, D. E. Shaw & Co., L.P., D. E. Shaw & Co., L.L.C., related corporate entities, and David E. Shaw may be deemed to share voting and dispositive power over 29,128,194 shares, or 6.0%, while each disclaims direct beneficial ownership.
Gossamer Bio, Inc. (GOSS) entered into a structured private placement with institutional and insider purchasers, involving pre-funded warrants, FDA Approval Warrants and non‑voting convertible preferred stock in three stages. The initial closing is expected to raise $25 million through pre-funded warrants priced at $0.1399 each.
A committed second closing upon FDA acceptance of the seralutinib NDA in PAH in 2026 is expected to raise an additional $125 million, with warrant pricing tied to market VWAP. FDA Approval Warrants, exercisable only after FDA approval, could provide up to a further $100 million in proceeds.
The financing uses Series A‑1, A‑2 and A‑3 preferred stock, each with a $1,000 stated value, conversion prices aligned to approximately $0.14–$0.187 per common share, pre‑closing liquidation preferences of 4x stated value, and strict beneficial ownership caps up to 19.99%. Gossamer plans to use the funds, together with existing cash, to advance and potentially commercialize seralutinib in PAH and PH‑ILD and expects the initial and committed capital to fund operations into 2028, subject to achieving regulatory and stockholder approval milestones.
Gossamer Bio reported second-quarter 2026 results and a major strategic refocus around seralutinib. Revenue from its Chiesi collaboration was $9.2 million, down from $11.5 million a year earlier, while research and development expenses fell to $26.4 million from $41.6 million. Net income was $16.9 million, compared with a net loss of $38.3 million in 2025, driven largely by a $43.8 million gain on debt extinguishment and remeasurement gains.
Cash, cash equivalents and marketable securities totaled $57.0 million as of June 30, 2026, which the company expects will fund operations into the first quarter of 2027. Gossamer exchanged $181.1 million of its 5.00% 2027 convertible notes for new 7.50% secured notes and equity, reducing debt principal by $115.9 million. It also reacquired worldwide rights to seralutinib from Chiesi, receiving a $5 million payment and retaining the substantial majority of global economics, and plans an NDA submission for seralutinib in PAH in September 2026 following a Pre‑NDA Type B FDA meeting.
Gossamer Bio, Inc. reported six‑month 2026 revenue of $26,193 (in thousands), entirely from its collaboration with Chiesi. Operating expenses were $97,133 (in thousands), leading to a loss from operations of $70,940 (in thousands). A $43,846 (in thousands) gain on extinguishment of 5.00% convertible notes drove second‑quarter net income of $16,900 (in thousands), but the company still recorded a six‑month net loss of $29,764 (in thousands).
Cash and cash equivalents were $41,148 (in thousands) and marketable securities $15,878 (in thousands) at June 30, 2026. Management states existing liquidity will fund operations only into the first quarter of 2027 and discloses substantial doubt about the ability to continue as a going concern. In June, Gossamer exchanged $181,052 (in thousands) of its 2027 notes for $65,174 (in thousands) of new 7.50% 2030 notes plus equity and warrants, leaving $18,948 (in thousands) of 2027 notes outstanding. The 2030 notes are classified as current because of a springing 2027 maturity. The company also reduced its workforce by 46%, recording $6.1 million in related charges, and later disclosed termination of the Chiesi collaboration, which had represented all revenue.
Gossamer Bio, Inc. has a significant shareholder group led by Opaleye Management Inc., Opaleye, L.P., and James Silverman. These reporting persons may be deemed to beneficially own 24,942,565 shares of Gossamer Bio common stock.
This position represents 5.10% of the outstanding common stock, based on 488,846,722 shares outstanding as of June 5, 2026. The Fund directly holds 24,141,629 shares, and an additional 800,936 shares are held in a separately managed account. The reporting persons have shared voting and dispositive power over these shares and no sole voting or dispositive power.